Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 10/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409656 | 0.92 | CCR5 (0.47) | OPRL1OPRM1CCR5HCRTR2HCRTR1 | |
| SCHEMBL6411476 | 0.91 | OPRL1 (0.51) | OPRL1OPRM1CCR5CCR3HSD11B1 | |
| Hydrochloric Acid SCHEMBL6415467 | 0.91 | CCR5 (0.46) | OPRL1OPRM1CCR5HCRTR2HCRTR1 | |
| SCHEMBL6408506 | 0.89 | HCRTR2 (0.38) | OPRL1OPRM1CCR5HCRTR2HCRTR1 | |
| Hydrochloric Acid SCHEMBL6410878 | 0.88 | HCRTR2 (0.38) | OPRL1OPRM1CCR5HCRTR2HCRTR1 | |
| SCHEMBL6408926 | 0.84 | UTS2R (0.49) | CCR5 | |
| SCHEMBL6409712 | 0.84 | POLB (0.40) | CCR5HCRTR2HCRTR1CCR3 | |
| Hydrochloric Acid SCHEMBL6415367 | 0.84 | UTS2R (0.48) | CCR5 | |
| SCHEMBL6409935 | 0.83 | HDAC11 (0.37) | CCR5HCRTR2HCRTR1 | |
| Hydrochloric Acid SCHEMBL6409854 | 0.83 | POLB (0.39) | CCR5HCRTR2HCRTR1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | OPRL1 151/4885OPRM1 244/4885CCR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.